Evotec Appoints Rui Wang as EVP Head of Global In Silico and AI

As CRO/CDMOs accelerate AI integration across R&D and manufacturing, Evotec SE has appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, a newly defined executive role that signals the company is embedding computational science at the strategic core of its operations, not treating it as a peripheral capability.

Wang brings more than 20 years of experience scaling data, analytics, and AI functions across pharmaceutical and biotech organisations. He joins from AstraZeneca, where he served as Head of Data, Analytics and AI following over a decade of progressively senior roles. Earlier positions include work at the European Molecular Biology Laboratory's European Bioinformatics Institute and Tangram Therapeutics. He holds M.Sc. degrees in Bioinformatics from the University of Manchester and in System Design for Internet Applications from Newcastle University.

In scope, the role spans both of Evotec's business segments: Drug Discovery and Preclinical Development, and Just, Evotec Biologics. CEO Christian Wojczewski framed the appointment in operational terms, describing advanced computational tools as embedded across discovery and development workflows rather than functioning as a standalone discipline. For QA directors and manufacturing leads at partner organisations, that framing carries a practical implication: AI-informed outputs from Evotec's platforms are expected to become more deeply integrated into joint programme deliverables.

Wang's own characterisation of the mandate is precise. He identified scale, biological relevance of training data, and differentiated platform capabilities as the conditions under which AI-enabled drug discovery produces durable advantage. Evotec's proprietary assets, including Molecular Patient Databases, PanOmics, and iPSC-based disease modelling, represent the data infrastructure against which that strategy will be tested.

For regulatory affairs leads and technical operations teams working with Evotec under existing partnership agreements, the appointment raises a near-term question around how AI-generated data packages will be documented and presented within submissions, an area where ICH Q10 alignment and data integrity standards will determine whether computational outputs translate cleanly into regulatory-acceptable evidence.

The degree to which Wang's mandate accelerates AI integration into Evotec's manufacturing and supply chain functions, particularly within Just, Evotec Biologics, will be a measurable indicator of whether the executive hire delivers the operational efficiency gains the company has signalled.

Source: Evotec SE via evotec.com, 2 June 2026.